Surrey researchers Sign in
Back
Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids
Journal article   Open access  Peer reviewed

Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids

AL Brackenridge, N Jackson, W Jefferson, M Stolinski, F Shojaee-Moradie, R Hovorka, AM Umpleby and D Russell-Jones
DIABETIC MEDICINE, Vol.26(5), pp.532-539
01/05/2009
DOI: https://doi.org/10.1111/j.1464-5491.2009.02729.x

Abstract

Science & Technology Life Sciences & Biomedicine Endocrinology & Metabolism ENDOCRINOLOGY & METABOLISM intermediate density lipoprotein low-density lipoprotein non-esterified fatty acid peroxisome proliferators-activated receptor-gamma agonist Type 2 diabetes very low-density lipoprotein IMPROVES GLYCEMIC CONTROL LOW-DENSITY LIPOPROTEIN INSULIN-RESISTANCE APOLIPOPROTEIN-B CONTROLLED-TRIAL THERAPY MELLITUS DYSLIPIDEMIA COMBINATION THIAZOLIDINEDIONES
pdf
Umpleby_Effects of135.93 kBDownloadView
TextSRIDA,  Open Access
url
http://dx.doi.org/10.1111/j.1464-5491.2009.02729.xView
Published (Version of record)
url
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000265981500013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11d2a86992e85fb529977dad66a846d5View
Author

Metrics

378 File views/ downloads
44 Record Views
13 Times Cited - Web of Science

Details

Usage Policy

Usage details for all content viewed and downloaded in this site are shared with IRUS-UK (Institutional Repository Usage Statistics UK). Cookies are used to remember your decision. Click Accept to accept usage details sharing and the cookies.

Learn more